Serial No. 10/686,801 Docket No. 4822-129 US

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this Application.

- 1. (Currently amended) A composition comprising a phenolic antioxidant-chromium complex that is therapeutic for treating hyperglycemia, wherein the phenolic antioxidant has no pro-oxidation activity and wherein the phenolic antioxidant is in a purified tannin fraction of plant origin.
- 2. (Currently amended) The composition complex of claim 1, wherein the hyperglycemia is due to a diabetic condition.
 - 3.-5. (Canceled).
- 6. (Currently amended) The <u>composition complex</u> of claim 1, wherein the chromium content in the complex is 0.01 to 20% of the complex.
- 7. (Currently amended) The eomposition complex of claim 6, wherein the chromium content in the complex is from 0.02 to 10%.
 - 8. (Canceled).
- 9. (Currently amended) The eomposition complex of claim 1, wherein the phenolic antioxidant tannin fraction comprises low molecular weight hydrolyzable tannin having a molecular weight below 2,000.
- 10. (Currently amended) The composition complex of claim 9, wherein the phenolic antioxidant is obtained from the genus Phyllanthus, Terminalia, Gardenia, Geranium, Erodium or Tamarix.
- 11. (Currently amended) The <u>composition—complex</u> of claim 9, wherein the hydrolyzable tannin is <u>obtained</u> from Phyllanthus emblica (syn. Emblica officinalis), Phyllanthus amarus, Phyllanthus flexusus, other Phyllanthus species, Terminalia bellerica, other Terminalia species, Erodium pelagonium, Geranium thumbergi, Tamarix aphyla or other Tamarix species.
 - 12. (Canceled).

Serial No. 10/686,801 Docket No. 4822-129 US

13. (Currently amended) The <u>composition complex</u> of claim 11, wherein the hydrolyzable tannin is <u>obtained</u> from the Phyllanthus emblica fruit.

- 14. (Currently amended) The composition of claim 1, A phenolic antioxidant-chromium complex that is therapeutic for treating hyperglycemia, wherein the phenolic antioxidant has no pro-oxidation activity and wherein the phenolic antioxidant comprises oxygenated dibenzo-α-pyrone (DBP) or a DBP conjugate and fulvic acid.
- 15. (Currently amended) The eomposition complex of claim 14, wherein the oxygenated dibenzo-α-pyrone (DBP) or DBP conjugate, comprises dimers and oligomers.
- 16. (Currently amended) The eomposition-complex of claim 1, wherein the phenolic anti-oxidant is in combination with a second phenolic anti-oxidant-chromium complex, wherein the second phenolic antioxidant is inobtained from Phyllanthus-emblica and purified fraction of fulvic acid and phenolic compounds from Shilajit.

17-21 (Cancelled)

- 22. (Currently amended) A formulation of the <u>composition_complex_of</u> claim 1, wherein the <u>phenolic antioxidant chromium complex is combined with and</u> a pharmaceutically or nutritionally acceptable excipient.
 - 23. (Cancelled).
- 24. (Currently amended) The eomposition complex of claim 1, further comprising an additional active ingredient.
- 25. (Currently amended) The composition-complex of claim 24, wherein the additional active ingredient is an antioxidant, vitamin, carnitine, carnosine, N-acetyl-L-cysteine, biotin, polycosanol, aminoguanidine, fatty acid or plant extract, or mixtures thereof.
- 26. (Currently amended) The composition complex of claim 7, wherein the chromium content in the complex is from 1 to 8% of the complex.
- 27. (Currently amended) The <u>composition_complex_of claim 191</u>, wherein the molecular weight of <u>the tannin in said tannin fraction</u> is below 1,000.

Serial No. 10/686,801 Docket No. 4822-129 US

28. (Withdrawn) A method of treatment for hyperglycemia which comprises administering to a mammal the composition of claim 1.

- 29. (Withdrawn) The method of claim 28, wherein the hyperglycemia is the result of a diabetic condition.
- 30. (Previously presented) The formulation of claim 22, wherein the phenolic antioxidant-chromium complex has 10 to 1,000 µg of chromium content.

31-32 (Cancelled)

- 33. (Currently amended) The composition—complex of claim 3114, wherein the phenolic antioxidant is oxygenated dibenzo-α-pyrone (DBP), a-DBP conjugate or fulvic acid of is from purified Shilajit.
- 34. (Currently amended) The composition complex of claim 31, wherein the phenolic antioxidant-chromium complex has 10 to 1,000 µg of chromium and is combined with a pharmaceutically or nutritionally acceptable excipient.
- 35. (Withdrawn) The method of claim 28, wherein the composition is administered once or twice a day.
- 36. (Currently amended) The <u>composition complex</u> of claim 15, wherein the oxygenated dibenzo-α-pyrone (DBP), DBP conjugate, and fulvic acid are obtained-from purified Shilajit.
 - 37. (Cancelled)
- 38. (New) The complex of claim 14, wherein the phenolic antioxidant-chromium complex has 10 to 1,000 μ g of chromium and is combined with a pharmaceutically or nutritionally acceptable excipient.